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he  deﬁnition  of  the  patient’s  physical  status  and  current
linical  condition  and  the  emergency  surgery  that  he  will  be
ndergoing,  translated  according  to  the  American  Society
f  Anesthesiologists  (ASA),  helps  in  the  deﬁnition  but  does
ot  deﬁne  mortality-predictability.1 Cardiac2 and  renal3 risk
ssessment  scales  have  been  used,  among  other  multifac-
orial  and  multidisciplinary  measures,4,5 but  they  tend  to
ave  no  speciﬁcity  and  sensitivity  coefﬁcients  that  give
he  caregiver  the  actual  predictability  of  the  preoperative
omplications  and  death.6
Several  retrospective,  prospective  and  observational
tudies  that  attempted  to  assess  perioperative  mortality7,8
emonstrated  the  importance  of  recognizing  the  patient’s
isk9--11 as  an  initial  measure  to  establish  protocols
nd  guidelines  related  to  hemodynamic  monitoring,  ﬂuid
eplacement  (ﬂuid  and  transfusion)  setting  goals  for  resus-
itation  (6D1),  and  multimodal  care  (ERAS/Hit  project),12--14
s  well  as  other  measures  that  could  facilitate  interactions
etween  monitoring  and  intervention  and  support  decision
aking  using  clinical  guidelines.15,16
Moreover,  several  other  studies  have  suggested  that  this
pproach  may  change  the  outcomes  and  signiﬁcantly  reduce
orbidity  and  mortality,  with  signiﬁcant  human  and  social
eneﬁts  interpreted  from  the  point  of  view  of  cost-effective
easures.9
It  is  estimated  that  about  240  million  surgical  proce-
ures  are  performed  annually  around  the  world,  where  the
tandard  mortality  rate  in  countries  and  areas  such  as  USA,
urope,  and  Brazil  for  patients  under  60  years  of  age  under-
oing  elective  surgery  and  without  chronic  and  clinically
igniﬁcant  changes  is  0.4--0.6%.6,7,17 For  patients  at  risk  (clin-
cal  status,  type  of  surgery,  or  a  combination  of  factors),
he  mortality  rate  in  noncardiac  surgery  can  be  greater  than
6%.6,7 Failure  to  identify  patients  at  risk,  lack  of  periopera-
ive  resources,  and  lack  of  intensive  postoperative  care  are
mong  the  factors  exacerbating  this  mortality.6,7,11 Periop-
rative  hemodynamic  optimization  has  contributed,  among
ther  things,  to  reduce  morbidity  and  mortality.
n
ﬂ
aA  retrospective  study  performed  in  the  UK  showed  that
mong  standard  surgical  patients  and  patients  at  risk,  the
atter  group  accounted  for  80%  of  deaths  of  surgical  patients
nd  over  80%  of  total  spending  in  the  UK.  In  the  same
tudy,  Pearse  stated  that  if  physicians  do  not  identify  the
atients  at  risk  and  therefore  do  not  offer  a  comprehensive
tandard  of  care,  this  will  signiﬁcantly  increase  morbidity
nd  mortality  in  this  population.  Consequently,  hemody-
amic  monitoring  and  ﬂuid  replacement  are  mandatory  in
atients  at  risk.
The  base  of  decision  making  is  the  previous  knowledge
f  high-risk  patients,  use  of  protocols  guided  by  the  hemo-
ynamic  monitoring  of  both  macro-  and  microcirculation,
nd  tissue  perfusion  evaluation  and  resuscitation  protocols
ith  ﬂuids  and  transfusions  based  on  oriented  decisions,18
articularly  those  related  to  ﬂuid  responsiveness.9,16,18,19
Fluid  titration  according  to  a  hemodynamic  goal  is  essen-
ial  to  improve  perioperative  outcomes.20 Some  studies  have
eported  better  outcomes  when  established  guidelines  of
‘restrictive’’  or  ‘‘limited’’  ﬂuid  therapy  were  compared
ith  standard  care  for  gastrointestinal  surgeries21--23 and
n  patients  with  pulmonary  dysfunction.24,25 These  studies
eem  to  argue  against  the  individually  tailored  goal-directed
herapy  based  on  intravascular  volume  optimization.  How-
ver,  studies  of  restrictive  ﬂuid  and  goal-directed  therapy
GDT)  essays  certainly  built  a  strong  case  for  a  priority  plan
f  perioperative  ﬂuids.  Taken  as  a  whole,  the  success  of  both
DT  and  some  restrictive  ﬂuid  strategies  suggests  that  peri-
perative  ﬂuid  planning  should  emphasize  that  ﬂuid  therapy
s  delivered  only  when  there  is  a  clear  indication.  As  for  the
rescription  of  antibiotics,  analgesics  and  other  therapeutic
rugs  to  a  speciﬁc  problem,  the  physician  should  consider
imilar  criteria  for  the  administration  of  ﬂuid.  There  are
‘gray  zones’’  when  it  is  unclear  whether  the  patient  will
espond  to  ﬂuid  therapy  or  not.  In  these  conditions,  the  use
f  functional  approaches  for  hemodynamic  monitoring  and
he  challenges  of  therapeutic  ﬂuids  seem  justiﬁed.  Hemody-
amic  parameters  provide  unique  functional  information  on
uid  responsiveness,  which  my  help  detect  ﬂuid  needs  and
void  unnecessary  ﬂuid  loading.  We  should  not  exclude  some
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Preoperative risk criteria
Major criteria
Older than 70 years with some decompensated disease;
Previous severe cardiorespiratory disease (Coronary artery disease / COPD / Stroke);
Severe vascular disease involving large vessels;
Acute abdomen with hemodynamic instability; 
Large blood loss (> 500 mL or > 7 mL.kg-1 younger than 12 years)
Septicemia;
Respiratory failure (need FiO2 > 40% to keep Sat >90% or mechanical ventilation time >48h;
Renal failure;
Extensive oncological surgery (e.g., gastrectomy, esophagectomy, cystectomy, etc.)
Esophagectomy
Gastrectomy
Resection
Liver
Pancreatectomy
Hip prosthesis revision
Open aortic surgery
Vascular bypass
Colectomy
Femur or hip fracture
Anesthetic time >2h;
Urgency/emergency surgery.
Minor criteria
Surgical risk
Critical Unit/
Hemodynamic 
Monitoring 
(GDT)
Inpatient unit
pera
Patient risk
Critical Unit/
Hemodynamic 
Monitoring 
(GDT)
Intensive care Unit/ 
Hemodynamic 
Monitoring 
(GDT)
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Figure  1  Matrix  for  the  d
limitations  related  to  functional  hemodynamic  parameters
(FHPs),  such  as  spontaneous  breathing,  non-standardized
tidal  volume,  non-standardized  airway  pressure/respiratory
rate,  non-sinus  rhythm,  neglected  dUp  (deltaUP),  and  right
heart  failure.26,27
Perioperative  GDT  aims  to  increase  oxygen  delivery  (DO2)
during  major  surgery  applying  a  tailored  hemodynamic  moni-
toring  and  therapeutic  interventions.  When  performed  early
and  in  the  right  group  of  patients  with  a  deﬁned  protocol,  it
has  shown  that  GDT  reduces  postoperative  mortality  in  the
group  of  higher  risk  patients16 and  morbidity  in  all  groups  of
surgical  patients.19,28
This  guideline  evaluated  the  clinical  efﬁcacy  of  hemody-
namic  GDT  in  reducing  morbidity  and  mortality  in  surgical
patients,  as  well  as  reducing  the  ﬁnancial  and  health  losses
associated  with  it.  We  have  also  proposed  a  set  of  surgi-
cal  procedures  and  patient  risk  factors  (i.e.,  age  and  ASA)
that  could  beneﬁt  GDT  (Fig.  1  and  Table  1).  Thus,  the  São
Paulo  State  Society  of  Anesthesiology  (SAESP)  invited  anes-
thesiologists  and  intensivists  involved  in  perioperative  care
to  establish  a  guideline  for  hemodynamic  monitoring  and
ﬂuid  resuscitation  in  high-risk  patients  as  a  contribution  to
t
a
t
ftive risk criteria
ion  of  high  risk  patients.35
ealth  professionals  and  policymakers  involved  in  the  care
f  patients  at  risk.
The  use  of  criteria  for  deﬁning  patients  at  risk  in  the  pre-
perative  period  is  crucial.  After  reviewing  several  studies
nd  published  papers,  we  concluded  that  the  creation  of  a
able  that  associates  high  and  low  risks  with  surgical  risk
ould  increase  the  sensitivity  and  speciﬁcity  of  character-
zing  the  high-risk  patient.
In  this  context,  we  recommend  using  this  table  associated
ith  this  care  matrix  and  decision  making.
uidelines  and  recommendations
t  has  been  shown  in  several  meta-analysis  that  the
se  of  protocols  for  perioperative  hemodynamic  support
hat  increases  tissue  perfusion  reduces  organ  dysfunctions,
ortality  and  hospitalization.29 These  outcomes  were  par-icularly  evident  when  applied  to  more  ill  patients.16 A  key
spect  of  any  perioperative  protocol  is  the  use  of  ﬂuid
herapy,  vasopressors,  and  inotropes,  which  should  also  be
ocused  on  physiological  hemodynamic  principles  (preload
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Table  1  Surgical  procedures  to  select  patients  who  may
beneﬁt  from  GDT.
High  surgical  risk
Esophagectomy
Gastrectomy
Liver  resection
Pancreatectomy
Colectomy
Rectal  resection
Cystectomy
Hyperthermic  Intraperitoneal  Chemotherapy  (HIPEC)
Femur  and  hip  fracture
Hip  revision
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Table  2  Search  strategy.
((((hemodynamic  goal-directed  therapy  OR  haemodynamic
goal-directed  therapy  OR  hemodynamic  goal  directed
therapy  OR  haemodynamic  goal  directed  therapy  OR
goal-directed  therapy  OR  goal  directed  therapy  OR
perioperative  hemodynamic  optimization  OR
perioperative  haemodynamic  optimization  OR
goal-directed  hemodynamic  OR  goal-directed
haemodynamic  OR  goal  directed  hemodynamic  OR  goal
directed  haemodynamic  OR  optimization  OR
haemodynamic  OR  hemodynamic  OR  haemodynamics  OR
TGOGDT  OR  hemodynamics  OR  goal-directed  ﬂuid
therapy  OR  goal-directed  ﬂuid  therapies  OR  goal  directed
ﬂuid therapy  OR  goal  directed  ﬂuid  therapies  OR  ﬂuid
therapy  OR  ﬂuid  therapies  OR  ﬂuid  challenge  OR  ﬂuid
management  OR  perioperative  hemodynamic
optimization  OR  perioperative  haemodynamic
optimization  OR  hemodynamic  stabilization  OR
haemodynamic  stabilization  OR  goal  oriented  OR  goal
targeted  OR  cardiac  output  OR  cardiac  outputs  OR
cardiac  index  OR  oxygen  delivery  OR  DO2  OR  oxygen
consumption  OR  oxygen  consumptions  OR  lactate  OR
lactates  OR  supranormal)  AND  (high  risk  surgical  patient
OR high  risk  surgical  patients  OR  high-risk  surgical
patient  OR  high-risk  surgical  patients  OR  high  risk
surgical  patient  OR  high  risk  surgical  patients  OR
high-risk  surgical  patient  OR  high-risk  surgical  patients))
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sAbdominal  Aortic  Aneurysm  (AAA)  open  repair
Shunt
nd  contractility)  as  an  interaction  between  the  autonomic
esponse  to  anesthetic  agents  and  volume  status.  There  is
o  global  consensus  on  broad  guidelines  of  ﬂuid  therapy,
hus  creating  local  standards  as  necessaries.  Although  we
re  offering  some  guidance,  the  physician  should  deﬁnitely
onsider  crucial  aspects  to  identify  and  treat  patients,  asso-
iated  with  the  following  variables:
1)  Patient  status  (health,  age,  physiology  status,  and
comorbidities):  these  factors  are  some  of  the  char-
acteristics  that  may  change  the  autonomic  response
and,  consequently,  hemodynamic  parameters;  there-
fore,  they  are  not  necessarily  related  to  ﬂuids.  Note
that  this  consideration  is  mandatory  for  patients  with
conditions  such  as  diabetes,  liver  dysfunction,  advanced
atherosclerosis,  and  preoperative  volume  depletion.
Moreover,  we  may  not  exclude  the  depth  of  anesthe-
sia  associated  with  peripheral  chemoreceptors  (e.g.,
neuromuscular  blockade),  baroreﬂex  (e.g.,  opioid),
impaired  cardiac  contractility  (e.g.,  general  anesthet-
ics),  or  sympatholysis  (e.g.,  intravenous  anesthetics).30
2)  Surgical  risk  (procedure  (Fig.  1  and  Table  1),  approach,
and  surgical  experience).
3)  Monitoring  selection:  the  use  of  static  parameters  (e.g.,
central  venous  pressure  and/or  pulmonary  artery  pres-
sure)  has  been  associated  with  lower  speciﬁcity  and
sensitivity  compared  to  the  use  of  the  ﬂuid  responsive-
ness  dynamic  parameters  (functional  hemodynamics  --
stroke  volume  variation  [SVV],  delta  PP,  etc.)  aiming
at  maintain  DO2 preoperatively.  For  high-risk  patients
undergoing  medium  or  large  surgery,  the  dynamic
parameters  associated  with  GDT  are  related  to  better
outcomes.31
4)  Biomarkers  for  tissue  perfusion  adequacy  (continuous
monitoring  of  lactate,  SvO2,  ScvO2,  CO2).
ethods
earch  strategye  searched  the  Cochrane  Central  Register  of  Controlled
rials  (CENTRAL),  Cochrane  Library  (2015,  Issue  5),  PubMed
1966  to  May  2015),  EMBASE  (1980  to  May  2015),  Web
s
m
c
sAND  (adult  OR  adults))  AND  (human  OR  humans))
f  Science  (1864  to  May  2015),  and  Latin  American  and
aribbean  Health  Sciences  (LILACS,  1982  to  May  2015).
here  was  no  language  restriction.  The  date  of  last  search
as  May  13,  2015.
Table  1  shows  the  electronic  databases  from  which  the
rticles  were  extracted  and  the  total  number  of  returned
eferences.
As  the  search  was  conducted  both  by  title  and  single
ords,  it  was  expected  that  all  GDT  studies  with  surgical
atients  were  identiﬁed.
Table  2  shows  the  literature  search  strategy  that  was
dapted  for  each  electronic  database.
ligibility  criteria
e  considered  including  only  randomized  controlled  trials
RCTs)  or  semi-randomized  controlled  trials  (semi-RCTs),  all
valuating  adult  patients  (>18  years)  undergoing  noncardiac
urgery  and  comparing  GDT  with  standard  care.
Semi-RCTs  are  those  in  which  the  treatment  assign-
ent  was  obtained  by  alternation,  use  of  alternate  medical
ecords,  alternate  birth  date  or  other  alternate  methods
redictable.
GDT  was  deﬁned  as  the  use  of  hemodynamic  optimization
trategies  aimed  at  improving  tissue  oxygenation  through  a
et  of  protocols  during  the  perioperative  period  to  reduce
orbidity  and  mortality,  hospitalization  stay  and  major
omplications.  One  of  the  requirements  for  GDT  consists  of
peciﬁc  parameters  to  guide  ﬂuid  therapy.
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We  included  studies  that  applied  GDT  at  the  follow-
ing  times:  preoperatively,  intraoperatively,  and  0--12  h  after
surgery.
The  GDT  interventions  analyzed  in  these  guidelines  are
as  follows:
1. Fluid  administration  alone;  and
2.  Combination  of  ﬂuid  and  vasopressor/inotropes.
We  consider  any  doses  of  the  interventions  described
above.  The  control  group  received  standard  care  or  a  con-
ventional  strategy  during  goal-directed  therapy.
We  considered  analyzing  the  following  types  of  outcomes:
mortality;  morbidities  (e.g.,  infections;  cardiovascular,  pul-
monary,  and  renal  complications;  anastomotic  leak;  nausea;
vomiting);  duration  of  hospital  stay  and  duration  of  inten-
sive  care  unit  (ICU)  stay;  duration  of  mechanical  ventilation
(calculated  when  the  mean  and  standard  deviation  were
reported  by  the  authors);  and  costs  (as  a  narrative  descrip-
tion).
Study  selection
Two  authors  independently  selected  the  potential  studies,
assessed  the  trial  quality,  and  extracted  data.
Strength  of  evidence  and  system  of  classiﬁcation
and recommendation
To  create  this  guideline,  the  studies  found  in  the  liter-
ature  were  classiﬁed  according  to  the  GRADE  system  of
the  strength  of  evidence  and  strength  of  recommendation
classiﬁcation.32--34
The  grading  system  classiﬁes  recommendations  as  strong
(Grade  1)  or  weak  (Grade  2)  according  to  the  balance
R
T
Table  3  Treatment  options  for  GDT  in  surgical  patients  according
Intervention  
Crystalloid  and  colloid  (not
speciﬁed)15
Inotropic  drugs  (dopexamin)
Colloids (hidroxietilamide)42 --  
Colloids (gelatin)3,37 Inotroic  (dopexamin)  
Colloids (hydroxyethyl  starch)32,46 Inotropic  (dobutamin)
and  vasoactive  drugs
Colloids (hydroxyethyl  starch)34,40 Inotropic  (dobutamin)  
Fluid42,48 --  
Crystalloid  and  colloid39 With  or  without  inotropic
agents  (dobutamine)
Colloid (hydroxyethyl  starch)46 Inotropic  agents  (dobutamin
and  vasoactive  drugs
Fluid (colloid)45 Inotropic  agents  (dobutamin
Colloid47 Inotropic  agents  (dobutamin
Fluid43 Inotropic  agents  (dobutamin
and  vasoactive  drugs
(dopamine)
Fluid44 --  
GRADE, degree of recommendation. guided  561
etween  beneﬁts,  risks,  burden  and  costs,  and  the  degree  of
onﬁdence  in  estimates  of  beneﬁts,  risks,  and  burden.  The
ystem  classiﬁes  quality  of  evidence  (as  reﬂected  in  conﬁ-
ence  in  estimates  of  effects)  as  high  (Grade  A),  moderate
Grade  B),  or  low  (Grade  C)  according  to  factors  that  include
he  risk  of  bias,  precision  of  estimates,  the  consistency  of
he  results,  and  the  directness  of  the  evidence.32--34
To  help  readers,  GRADE  results  of  evidence  were  rep-
esented  using  a color  system  in  which  green  indicates
trong  recommendation  (i.e.,  1),  red  indicates  weak  rec-
mmendation  (i.e.,  2),  and  yellow  indicates  studies  with
igh  probability  recommendation  based  on  evidences,  but
his  recommendation  was  downgraded  due  to  some  problem
n  its  internal  and/or  external  validity  (Grade  1  B/C  or  2,
egardless  if  A,  B,  or  C).
ethods  used  for  evidence  analysis
n  evidence  table  was  developed  for  GDT  based  on  a  current
iterature  review  and  expert  panel  consensus  (Tables  3--7).
henever  possible,  we  calculated  the  relative  risk  (RR)  for
ortality  and  morbidity,  as  well  as  the  mean  difference  (MD)
etween  duration  of  hospital  and  ICU  stay  and  its  conﬁdence
ntervals  (CI)  of  95%.  Furthermore,  the  number  of  patients
ho  required  treatment  to  prevent  further  poor  outcome
e.g.,  the  number  of  patients  that  needed  to  be  treated  for
ne  to  beneﬁt  compared  to  a  control  in  a  clinical  trial)  was
alculated  to  obtain  statistically  signiﬁcant  results.
The  average  age  calculated  in  this  study  was  based  on  the
verage  age  of  both  groups  (i.e.,  intervention  and  control
rms)  of  each  study  included  in  this  guideline.esults
ables  3--7.
 to  level  of  evidence  and  grade  of  recommendation.
Period  GRADE  Clinical  condition
 Intraoperative  and
0--12  h  after  surgery
1A  Elective  and  non
elective
Intraoperative  1A  Non  elective
0--12  h  after  surgery  1B  Elective
Intraoperative  and
0--12  h  after  surgery
1B  Elective
Preoperative  1B  Elective
Intraoperative  1B  Elective
0--12  h  after  surgery  2A  Elective
e) Intraoperative  and
0--12  h  after  surgery
2A  Elective
e)  Intraoperative  2B  Non  elective
e)  0--12  h  after  surgery  2B  Elective
e) Intraoperative  and
0--12  h  after  surgery
2B  Elective
Intraoperative  2B  Elective
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Table  4  Relative  risk  and  the  number  needed  to  treat  mortality  in  GDT  surgical  patients  according  to  the  degree  of
recommendation.
Period  and  intervention  Follow-up  Relative  risk  (RR)  (CI
95%)
NNT  Reference
Intraoperative:  ﬂuid  (colloids)  30  days  0.50  (0.05--5.37) a Benes  201012
Intraoperative  and  0--12  h  after  surgery:
ﬂuid  (colloid  and  inotropic  [dopexamine])
30  days  1.08  (0.48--2.43) a Pearse  201415
Intraoperative:  ﬂuid  and  inotropic  30  days  Not  estimable a Cecconi  201140
Intraoperative:  ﬂuid  (colloids)  At  hospital  0.50  (0.05--5.08) a Sinclair  199742
Intraoperative:  ﬂuid  (starches)  30  days  0.38  (0.08--1.67) a Lopes  200744
Intraoperative:  ﬂuid 30  days 0.20  (0.01--3.97) a Scheeren  201348
0--12  h  after  surgery:  ﬂuid  (gelofusine)  and
inotropic  (dopexamine)
28  and  60  days 0.83  (0.30--2.33)  and
0.75  (0.30--1.89)
a Pearse  200537
0--12  h  after  the  surgery:  ﬂuid  and  inotropic  30  days  1.73  (1.24--2.40)  6.2  Donati  200747
Intraoperative  and  0--12  h  after  surgery:
ﬂuid,  inotropic  and  vasoactive  drugs
30  days  0.47  (0.14--1.62) a
Lobo  20004360  days  0.32  (0.10  to  0.98)  2.8
a The number needed to treat (NNT) was not calculated because there was no signiﬁcant difference between groups. When there is no
 is inﬁnite.
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# of records
identified
through
database
searching 13,791
# of additional
records
identified
through other
sources 0
# of records after duplicates
removed 12,165
# of records
screened 12,165
# of full–text
articles assessed
for eligibility 600
# of studies
included in this
# of records
excluded 11,565
# of records excluded, and
reasons 586
409 Off–topic
45 reviews
76 case report or letter for
the editor
56 observational studies
PubMed 5,394
EMBASE 7,128
CENTRAL 111
Web of Science
330
LILACS 828treatment effect, the absolute risk reduction is zero and the NNT
tudy  selection
e  identiﬁed  a  total  of  12,165  records,  after  removing  dupli-
ates,  through  database  searches  for  original  review  (Fig.  2).
fter  sorting  by  title  and,  subsequently,  by  abstract,  we
ound  full  copies  of  600  records  that  were  potentially  eli-
ible  for  inclusion  in  the  guideline.  We  excluded  584  studies
or  the  following  reasons:  off-topic;  editorials  or  letters;
arrative  reviews;  case  study;  cardiac  studies;  duplicates;
ublished  protocols;  and  cohort  and  case--control  studies.
herefore,  15  RCTs  and  semi-RCTs  met  the  inclusion  criteria
or  this  guideline  (Table  8).
ow  to  select  patients  who  may  beneﬁt  from  GDT?
RADE:  1C
Response: We  recommend  using  GDT  according  to
atient’s  risk  and  surgical  risk  because  these  factors
an  improve  the  following  outcomes:  mortality,  morbid-
ty  (e.g.,  infection;  cardiovascular,  pulmonary  and  renal
omplications;  anastomotic  leaks;  nausea;  vomiting);  length
f  hospital  and  ICU  stay;  and  duration  of  mechanical
entilation35 (Fig.  2).  We  recommend  the  use  of  GDT  in
atients  aged  over  65  years  and  ASA  ≥  II  and  patients  under-
oing  ≥2  h  of  surgery  or  with  expected  blood  loss  over  500  mL
r  urgent/emergency  surgery  or  one  of  the  surgical  proce-
ures  listed  in  Table  1.36
s  GDT  more  effective  and  safer  than  standard  care  to
educe  mortality  and  morbidity  in  high-risk  surgical
atients?
RADE:  1A
Response: Yes.  The  use  of  GDT  reduces  morbidity  in  dif-
erent  age  group  patients,  while  it  reduces  mortality  only  in
ery  high-risk  patients.15,37--42
Arguments: Reduction  in  mortality  with  GDT  in  high-
isk  patients  was  seen  in  patients  with  early  mortality
ates  >  20%.41,43 This  high  mortality  rate  is  consistent  with
ortality  rates  of  patients  undergoing  high-risk  surgery,  pre-
iously  reported  in  Brazil.43,44 The  use  of  protocols  with
guideline 14
Figure  2  Flowchart  of  the  assessed  studies  for  these  guide-
lines.
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Table  5  Trends  for  lower  and  higher  morbidity  in  GDT  surgical  patients  according  to  the  degree  of  recommendation:  relative
risk and  number  needed  to  harm  occurrence.
Period  Intervention  Outcome  Relative  risk  (RR)  (CI
95%)
NNT  Reference
0--12  h  after
surgery
Fluid  (crystalloid  and
colloid),  and  inotropic
drugs  (with  or  without
dobutamine)
Morbidity  deﬁned  in
POMS  (postoperative
morbidities  Survey)
1.04  (0.96--1.11) b Ackland  201539
Pulmonary  1.11  (0.96--1.29)
Renal  1.03  (0.91--1.17)
Gastrointestinal  1.11  (0.89--1.38)
Cardiovascular  1.09  (0.68--1.74)
Hematologic  1.33  (0.56--3.16)
Pain 1.14  (0.98--1.33)
Intraoperative  and
0--12  h  after
surgery
Fluid  (colloid  and
inotropic  (dopexamine)
Compound  outcomes
(postoperative
mortality  within  30
days  and  predeﬁned
serious  postoperative
complicationsa)
0.84  (0.71--1.01) b Pearse  201415
Fluid  (colloid  and
inotropic  (dopamine)
Ischemia  or
myocardial  infarction
1.24  (0.50--3.11)
Cardiac  or  respiratory
arrest
1.14  (0.56--2.29)
Gastrointestinal
bleeding
1.62  (0.68--3.85)
Fluid (crystalloid,
colloid)  and  inotropic
(dobutamine)
Complications  1.13  (0.69--1.85)  Bisgaard  2013a,38
Intraoperative  and
0--12  h  after
surgery
Fluid  (crystalloids  and
colloids),  and  inotropic
drugs  (with  or  without
dobutamine)
Infection  0.97  (0.66--1.41) b Ackland  201539
Neurologic  0.51  (0.24--1.09)
Wound  0.97  (0.20--4.68)
Fluid (colloids)  and
inotropic  (dobutamine)
Complications  0.99  (0.26--3.78) b Donati  200747
Cardiocirculatory
failure
0.20  (0.02--1.64)
Respiratory  failure  0.99  (0.26--3.78)
Renal  failure  0.28  (90.6--1.31)
Liver  failure  0.25  (0.05--1.12)
Hematological  failure  0.14  (0.01--2.67)
Fluid (gelofusine)  and
inotropic  (dopamine)
Complications
(infection,
respiratory,
cardiovascular,
abdominal,  and
massive
postoperative
bleeding)
0.64  (0.46--0.89)  4  Pearse  200537
Fluid  and  inotropic Total  and  major
complications
Total:  0.13  (0.02--0.91)
Important:  0.80
(0.64--1.02)
2.8  Cecconi  201140
Fluid,  inotropic  and
vasoactive  drugs
Arrhythmia  0.14  (0.01--2.46) b Lobo  200043
Shock  0.14  (0.01--2.46)
Stroke  0.32  (0.01--7.30)
Bronchopneumonia  0.63  (0.21--1.88)
Wound  infection  0.19  (0.01--3.71)
Fistula  0.71  (0.18--2.74)
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Table  5  (Continued)
Period  Intervention  Outcome  Relative  risk  (RR)  (CI
95%)
NNT  Reference
Intraoperative Fluid  (starches) Respiratory
complications
0.38  (0.23--0.95)  2.5 Lopes  200744
Renal  complications 0.09  (0.01--0.59) 1.5
Arrhythmia  0.47  (0.14--1.57)
bInfection  0.47  (0.21--1.08)
Acute  pulmonary
edema
0.19  (0.01--3.66)
Abdominal  0.31  (0.01--7.21)
Fluid and  inotropic  Survivors  with
complications
0.80  (0.54--1.19) b Bartha  201345
Fluid  (colloids) Serious  complications  0.32  (0.15--0.69)  4 Benes  201012
Complications  0.51  (0.33--0.80)  3.6
Fluid Wound  infection  0.07  (0.00--1.11) b Scheeren  201348
Inotropic  (dobutamine)
and  vasoactive  drugs
Complications  0.40  (0.20--0.82)  2.22  Bisgaard  2013b46
a Pulmonary embolism, ischemia or myocardial infarction, arrhythmia, cardiac or respiratory arrest, limb or ﬁnger ischemia, cardiogenic
pulmonary edema, respiratory acute stress syndrome, gastrointestinal bleeding, intestinal infarction, anastomosis breakdown, paralytic
ileus, acute psychosis, stroke, acute kidney injury, infection (source uncertain), urinary tract infection, surgical site infection, organ or
space infection, blood infection, nosocomial pneumonia, and postoperative bleeding.
b The number needed to treat (NNT) was not calculated because there was no signiﬁcant difference between groups. When there is no
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atreatment effect, the absolute risk reduction is zero and the NNT
upranormal  physiological  targets  decreased  morbidity  in
igh-risk  patients.16 A  careful  hemodynamic  monitoring
efore,  during,  and  after  surgery  to  adjust  ﬂuid  therapy
acilitates  the  recognition  and  early  correction  of  tissue
ypoperfusion.  The  reduction  in  complication  rates  was
eeper  in  high-risk  patients,  protocols  with  supranormal
hysiological  targets,  and  cases  receiving  inotropic  agents
n  addition  to  ﬂuid.  Although  the  use  of  inotropic  agents  has
ot  been  recommended  in  the  study  OPTIMISE,  when  the
tudy  was  later  added  to  the  systematic  review  and  meta-
nalysis  of  the  study  group,  the  intervention  was  associated
ith  a  reduction  in  complication  rates.15
s  GDT  effective  and  safe  when  applied  intraoperatively
o  reduce  mortality  and  morbidity  in  high-risk  surgical
atients?
RADE:  1B
Response: Yes,  GDT  is  safe  and  effective  when  applied
ntraoperatively  to  reduce  postoperative  complications  in
igh-risk  surgical  patients.12,15,38,40,42,43,45--48Arguments: Several  studies  have  suggested  that  GDT
pplied  upon  increased  blood  ﬂow  may  reduce  postoperative
omplications.  Most  of  these  studies  were  conducted  dur-
ng  the  intraoperative  period.49--51 All  these  studies  shared
s
t
v
u
Table  6  Mean  difference  in  length  of  hospital  and  ICU  stay  in  GDT  
Intervention  Type  of  outcome  
Intraoperative:  ﬂuid  ICU  
0--12  h  after  surgery:  ﬂuid  and  inotropic  Hospital  ﬁnite.
he  need  for  enhanced  monitoring  with  a gavage49,52 arte-
ial  catheter,43,50,51 or  pulmonary  artery  catheter  (PAC).12
hese  studies  concluded  that  hemodynamic  optimization
uring  surgery  improves  the  surgical  outcomes  in  high-risk
atients,  and  all  forms  of  monitoring  appear  to  be  effec-
ive.  Goal-directed  therapy  typically  uses  a  monitoring  tool
or  assessing  cardiac  function  continuously  and  via  a  set  of
rotocol  instructions,  administration  of  ﬂuid  and  vasoactive
gents  is  titrated  to  optimize  cardiac  performance.  Central
o  these  studies  is  that  the  GDT  should  not  be  deﬁned  by  the
resence  or  absence  of  a  monitoring  device  but  by  explicit
reatment  objectives,  such  as  maintenance  of  cardiac  index
nd  blood  volume  dynamic  parameters.  Generally,  in  these
urgical  patients,  GDT  should  be  provided  during  all  pro-
edures,  from  induction  to  6--24  h  in  the  ICU.  Recently,
earse  et  al.15 reported  the  OPTIMISE  results,  a  pragmatic
ulticenter  trial  performed  in  17  hospitals  with  734  ran-
omly  chosen  high-risk  patients  undergoing  gastrointestinal
urgery  to  receive  standard  care  or  GDT  intraoperatively
nd  for  6  h  after  surgery.  The  intervention  tested  in  this
tudy  consisted  of  a  dopexamine  infusion  +  bolus  adminis-
ration  of  colloid  (250  mL)  to  maintain  maximum  stroke
olume  (SV)  during  the  study  period.  SV  was  determined
sing  an  advanced  monitor.  The  primary  endpoint  incidence
surgical  patients  according  to  the  degree  of  recommendation.
Mean  difference  (ND)  (95%  CI)  Reference
−12.00  (−34.89--10.89)  Scheeren  201348
−2.10  (−3.82  to  −0.38)  Donati  200747
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Table  7  Intervention  characteristics  of  the  included  studies  by  period  of  time.
Elective or
non-elective
surgery
Surgery type Mean age Intervention Monitor
Type
Technique Main target Calibrated GRADE Reference
Preoperative and intraoperative
Non-elective Orthopedic 74.7 Fluid (colloid) Doppler Minimally
invasive
Systolic volume;
correct ﬂow of
time; CO
Yes 1B Sinclair
199742
Elective Total hip
arthroplasty
66 Fluid and
inotropic
Vigileo/
FloTrac
system
Minimally
invasive
DO2 > 600 mL/
min/m2
No 1A Cecconi
201140
Elective Retroperitoneal,
aortic major
open surgery,
major renal,
bladder surgery,
and
hysterectomy
and
oophorectomy
for cancer
No  report Fluid Not applied Not applied Not applied Not
applied
2B Cuthbertson
201156
Intraoperatory
Elective Abdominal
important and
radical
cystectomy
70.5 Fluid (colloid) Vigileo/
FloTrac
system
Minimally
invasive
Variation  in
stroke volume
No 1B Scheeren
201348
Elective Intra-abdominal 66.5 Fluid (colloid) Sistema
Vigileo/
FloTrac
system
Minimally
invasive
Variation  in
stroke volume
Not
reported
1B  Benes 201012
Non-elective Orthopedic 85.5 Fluid (colloid)
and inotropic
(dobutamine)
Lidco Minimally
invasive
Oxygen delivery Yes 2B Bartha
201262
Elective Upper and lower
gastrointestinal,
hepatobiliary,
urological
62.5 Fluid (starch) Pulse
pressure
variation
Minimally
invasive
Delta  PP ≤ 10% Not
applied
2B Lopes 200744
Intraoperative and 0--12 h after surgery
Both Upper and lower
gastrointestinal,
small intestine
with or without
pancreas,
urologic,
gynecologic.
71.7 Fluid (colloid)
and inotropic
(dopamine)
Lidco rapid Minimally
invasive
Systolic volume No 2B Pearse
201415
Elective Aortic 68 Fluid
(hydroxyethyl
starch) and
inotropic
(dopamine)
and
vasopressors
Lidco  plus Minimally
invasive
DO2 Yes 2B Bisgaard
2013a38
Elective Upper and lower
gastrointestinal
and vascular.
72.5 Fluids
(crystalloids,
colloids),
inotropic
(dobutamine)
and
vasopressors
Lidco  plus Minimally
invasive
DO2 Yes 1B Bisgaard
2013b46
Elective Total
esophagectomy,
gastrectomy,
pancreatectomy,
bowel resection,
abdominal
aortic aneurysm
62.7 Fluid,
inotropic
(dobutamine)
and
vasopressors
(dopamina)
Pulmonary
artery
catheter
Invasive  DO2 No 2B Lobo 200043
0--12 h after surgery
Elective Vascular, upper
and lower
gastrointestinal,
hepatobiliary,
urological
61 Fluid
(gelofusine)
and inotropic
(dopexamine)
Lidco plus Minimally
invasive
Oxygen delivery
index; systolic
volume
Yes 1B Pearse
200537
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Table  7  (Continued)
Elective or
non-elective
surgery
Surgery type Mean age Intervention Monitor
Type
Technique Main target Calibrated GRADE Reference
Elective Abdominal
aortic aneurysm,
intestinal
resection for
cancer,
pancreaticoduo-
denectomy,
aortoiliac bypass
66 Fluid
(colloids) and
inotropic
(dobutamine)
Not applied CVC O2Ext
(SaO2 − ScvO2/
SaO2) < 27%
Not
applied
1B  Donati
200747
Elective Upper
gastrointestinal,
liver and
hepatobiliary
resection, lower
gastrointestinal
and vascular
68 Fluid
(crystalloids
and colloids)
and inotropic
(dobutamine)
Lidco plus Minimally
invasive
Cardiac output Yes 2A Ackland
201539
(a  composite  of  pre  speciﬁed  postoperative  complications
within  30  days  of  the  surgery)  was  lower  in  GDT  group  (36.6%
vs.  43.4%  [relative  risk  (RR)  0.84;  (95%  CI,  0.71--1.01)];
absolute  risk  reduction,  6.8%  [95%  CI,  −0.3%  to  13.9%]).
This  reduction,  consistent  with  the  beneﬁts  observed  in
many  previous  trials,12,38,40,42,43,44--48 was  still  signiﬁcant  after
adjustment  for  initial  risk  factors  or  after  deleting  the  ﬁrst
10  patients.
The  authors  performed  an  additional  analysis,  includ-
ing  the  OPTIMISE  results  in  an  updated  systematic  review.15
These  results  further  strengthened  the  general  conclusion
that  GDT  of  some  sort  is  likely  to  be  beneﬁcial  to  high-risk
patients  and  has  few  adverse  effects  documented.  Findings
of  a  meta-analysis  of  38  trials,  including  data  from  OPTIMISE
study  suggest  that  the  intervention  is  associated  with  a  lower
incidence  of  complications  (intervention,  488/1548  [31.5%]
vs.  control,  614/1476  [41.6%];  RR,  0.77  [95%  CI,  0.71--0.83])
and  non-signiﬁcant  reductions  in  mortality  within  28  days
and  30  days  (intervention,  159/3215  deaths  [4.9%]  vs.  con-
trol,  206/3160  deaths  [6.5%];  RR,  0.82  [95%  CI,  0.67--1.01])
and  mortality  in  the  longer  follow-up  period  (interven-
tion,  267/3215  deaths  [8.3%]  vs.  control,  327/3160  deaths
[10.3%];  RR,  0.86  [95%  CI,  0.74--1.00]).  These  ﬁndings  are
consistent  with  reports  from  Centers  for  Medicare  &  Med-
icaid  Services53 and  National  Institute  for  Health  and  Care
Excellence,54 which  recommended  the  use  of  hemodynamic
therapy  algorithms.
Table  8  Electronic  databases,  date  of  last  search,  and
number  of  returned  references.
Electronic
databases
Date  of  last
search
Number  of
returned
references
PubMed  1966  to  May  2015  5394
CENTRAL  Issue  05,  2015  111
EMBASE  1980  to  May  2015  7128
Web of  Science  1864  to  May  2015  330
LILACS  1982  to  May  2015  828
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cs  GDT  effective  and  safe  when  applied  postoperatively
o  reduce  mortality  and  morbidity  in  high-risk  surgical
atients?
RADE:  1A
Response: Yes.  We  recommend  applying  GDT  after
urgery  in  high-risk  surgical  patients.
Arguments: Studies  have  shown  that  this  strategy  may
ontribute  to  reduce  morbidity15,37 GDT  should  be  applied
n  the  ﬁrst  8  h  postoperatively  and  requires  hemodynamic
onitoring  to  guide  ﬂuid  replacement,  inotropes,  vasopres-
ors,  and  vasodilators.  In  a  cost-beneﬁt  analysis,  Ebm  et  al.55
eported  that  GDT  could  reduce  costs  by  £ 2631.77/patient
nd  £ 2134.86/in-hospital  survival,  indicating  that  it  is  effec-
ive  both  clinically  and  in  terms  of  cost.  Additional  costs  of
mplementation  can  be  offset  by  savings  from  cost  reduc-
ion  due  to  reduction  in  complication  rates  and  hospital
tay.  In  addition,  this  study  showed  that  GDT  not  only  pro-
onged  quality-adjusted  life  expectancy  (0.83  years  and  9.8
onths),  but  also  led  to  a  cost  reduction  projection  dur-
ng  life  of  £ 1285.77,  resulting  in  a  negative  incremental
ost-beneﬁt  rate  of  £ 1542.16/quality-adjusted  life-year.55
hould  we  hemodynamically  monitor  patients  to  apply
DT  in  high-risk  surgical  patients?
RADE:  1A15,40,43,44
Response:  Yes,  every  patient  who  will  undergo  GDT
hould  be  hemodynamically  monitored.  We  recommend  any
onitor  that  is  available  to  estimate  the  cardiac  output  (CO)
r  different  tools  associated  with  pulse  oximeter  (plethys-
ograph  variability  index  --  PVI),  bedside  monitors  (pulse
ressure  variation  --  PPV)  and  CO  monitors  (stroke  volume
ariation  --  SVV,  SV,  oxygen  supply  --  DO2).  In  addition,  other
ools  have  been  used  to  guide  GDT,  such  as  PAC,  esophageal
oppler,  and  methods  for  pulse  curve  analysis.  It  is  note-
orthy  that  no  invasive  monitoring,  such  as  pulse  oximetry
ith  plethysmographic  analysis  or  methods  associated  with
eg  elevation  maneuvers  should  be  used  as  a  functional
emodynamic  parameters  (FHP).12,15,37--40,42,43,45--48,56,57 How-
ver,  some  of  the  perioperative  goal-directed  strategies
ailed  because  they  are  based  on  maximizing  CO/SV  without
onsidering  ﬂuid  responsivity.58 Still,  Cannesson59 reported
goal
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that  ‘‘(.  . .) feedback  from  anesthesiology  providers  was  that
this  protocol  [NICE  NHS  protocol  suggesting  ﬂuid  to  maxi-
mize  SV]  forced  them  to  give  more  ﬂuids  than  thought  should
be  given,  and  team  leaders  decided  to  include  the  stroke
volume  variation  (SVV)  as  the  trigger  to  ﬂuid  administration
to  increase  physicians’  adherence.59
Arguments: All  studies  used  some  type  of  device  to
monitor  hemodynamic  parameters.  To  apply  GDT,  it  is  nec-
essary  ﬁrst  to  establish  a  protocol  for  delivery  of  oxygen
and  prevent  tissue  hypoperfusion,  and  many  protocols  have
been  published  in  the  literature.  In  general,  ﬂuid  and
inotropes  are  used.  Fluid  should  be  administered  when
patients  require  increased  perfusion  and  are  also  responsive
to  volume.60
Fluid  responsiveness  may  be  assessed  by  PPV,  SVV,  PVI
or  by  the  superior  vena  cava  compressibility.  It  is  impor-
tant  to  adjust  and  make  sure  that  patients’  parameters  are
eligible  for  the  assessment  of  the  ﬂuid  responsiveness  varia-
bles,  without  respiratory  triggers,  arrhythmias  or  open  chest
surgery,  and  tidal  volume  of  at  least  8  mL/kg  estimated  by
height.  Postoperatively,  if  the  patient  is  breathing  sponta-
neously,  a  strategy  called  ‘‘passive  elevation  of  the  legs’’
may  be  used  as  a  means  to  change  the  ventricular  preload
associated  with  the  measurement  of  the  change  in  stroke
volume,  which  provides  an  accurate  means  to  guide  the  ther-
apy  providing  ﬂuid  rates  in  high-risk  patients.  Patients  are
considered  responsive  if  the  cardiac  output  increases  from
10%  to  15%  of  baseline  values.  When  dynamic  parameters
(PPV,  SVV,  PVI)  may  not  be  used,  a  CO  monitor  is  required
to  quantify  changes  in  stroke  volume  or  DO2.  An  important
aspect  to  be  avoided  while  applying  GDT  is  ﬂuid  overload;
that  is,  when  patients  do  not  derive  beneﬁt  from  the  ﬂuid
administration;  otherwise,  there  is  no  increase  in  cardiac
output.
What  tools  should  be  used  for  GDT?
GRADE:  1A
Response: We  recommend  any  monitor  that  is  available
to  estimate  the  cardiac  output  or  different  tools  associated
with  pulse  oximeter  (PVI),  bedside  monitors  (PPV),  and  CO
monitors  (SVV,  SV,  DO2).  To  apply  GDT  properly,  the  doctor
must  rely  on  SV  optimization  based  on  DO2 or  PPV  optimiza-
tion  (the  ﬁrst  requires  a  CO  monitor,  but  not  the  latter).  In
addition,  other  tools  have  been  used  to  guide  GDT,  such  as
PAC,  esophageal  Doppler,  and  methods  of  pulse  curve  analy-
sis.  Therefore,  all  these  methods  may  be  used  as  they  have
been  associated  with  reductions  in  morbidity  and/or  hospital
stay.12,15,37--40,42,43,45--48,56
Arguments: Studies  have  been  based  on  protocols  and  not
on  speciﬁc  devices;  no  monitoring  technique  by  itself  can
improve  outcomes.  Some  devices  offer  more  advantages,
such  as  being  less  invasive  or  minimally  invasive.  For  exam-
ple,  pulse  curve  analysis,  transpulmonary  thermodilution,
and  esophageal  Doppler  feature  parameters  to  apply  GDT.
However,  these  methods  are  generally  more  expensive  and
are  not  offered  by  the  Uniﬁed  Health  System  (SUS)  --  Min-
istry  of  Health.  In  this  scenario,  pulmonary  artery  catheters
may  be  used  to  replace  minimally  invasive  techniques.  Mon-
itoring  requirements  may  vary  with  time  and  depend  on  the
local  availability  of  equipment  and  training.  It  is  very  impor-
tant  to  emphasize  that  the  entire  team  should  be  familiar
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nd  trained  to  insert  devices,  manage  and  interpret  data,
nd  apply  strategies.  This  recommendation  is  for  all  types
f  monitoring,  even  if  it  is  a  minimally  invasive  technique.  It
s  important  to  monitor  the  hemodynamic  changes  over  short
eriods  of  time,  and  interventions  should  be  made  when
ecessary.  A  continuous  measurement  of  all  hemodynamic
ariables  is  preferable  because  one  does  not  want  to  waste
ime  to  correct  any  instability  or  achieve  a goal.  Monitors
or  continuous  monitoring  of  cardiac  output  are  preferred,
lthough  there  are  no  data  to  support  the  superiority  of
ardiac  output  continuous  measurement  over  intermittent
onitoring.  These  measures  could  be  justiﬁed,  however,  if
udden  changes  could  be  detected  early  and  intervention
ould  readily  be  provided.14
hat  comorbidities  are  reduced  associated  with  the  use
f  GDT?
RADE:  1B
Response: Perioperative  GDT  reduces  the  following
omplications  after  surgery:  infections;  wounds;  gas-
rointestinal  bleeding  and  cardiocirculatory  failure;  and
ulmonar,  neurological,  renal  and  hematological  insufﬁcien-
ies  (Table  5).
Arguments: Surgical  procedures  in  high-risk  patients
re  associated  with  high  incidence  of  postoperative
omplications.  It  was  proved  that  GDT  signiﬁcantly
educes  the  number  of  surgical  patients  with  postoperative
omplications.  Thirty-one  studies  with  5292  participants
ere  enrolled  in  a  Cochrane  publication  of  201261 to
escribe  the  effects  of  increased  perioperative  blood  ﬂow
sing  ﬂuid  with  or  without  inotropic  or  vasoactive  drugs.
he  number  of  patients  with  complications  has  been
educed  through  the  intervention,  with  a RR  of  0.68  (95%
I  0.58--0.80).  Hospital  stay  was  reduced  in  the  treat-
ent  group,  on  averaged,  by  16.1  days  (95%  CI  0.43--1.89;
 =  0.002).  In  addition,  three  morbidity  rates  were  reduced
y  increasing  the  overall  blood  ﬂow:  kidney  failure,  with  a
R  of  0.71  (95%  CI  0.57--0.90);  respiratory  failure,  with  a
R  of  0.51  (95%  CI  0.28--0.93);  and  wound  infections,  with
 RR  of  0.65  (95%  CI  0.51--0.84).  These  data  indicate  that  in
00  patients  exposed  to  treatment,  it  can  be  expected  that
3/100  avoid  a complication,  2/100  prevent  renal  impair-
ent,  5/100  prevent  respiratory  failure,  and  4/100  prevent
ostoperative  wound  infection.
An  updated  literature  search,  recently  published  by
earse,15 identiﬁed  38  trials  that  included  6595  participants,
ith  23  trials  including  3024  participants  and  providing
ata  on  postoperative  morbidities.  Complications  were  less
requent  in  patients  treated  according  to  a  hemodynamic
herapy  algorithm  (intervention  488/1548  [31.5%]  vs.  con-
rol  614/1476  [41.6%];  RR  0.77  [95%  CI,  0.71--0.83]).  The
ntervention  was  also  associated  with  a  reduced  incidence
f  postoperative  infection  (intervention,  182/836  [21.8%]
s.  control,  201/790  [25.4%];  RR,  0.81  [95%  CI,  0.69--0.95])
nd  a  reduced  hospital  stay  (average  reduction  of  0.79
ays  [95%  CI,  0.96--0.62]).  There  was  no  signiﬁcant  reduc-
ion  in  mortality  within  28  days  and  30  days  (intervention,
59/3215  [4.9%]  vs.  control,  206/3160  [6.5%];  RR,  0.82  [95%
I,  0.67--1.01])  and  mortality  in  the  longer  follow-up  period
intervention,  267/3215  deaths  [8.3%]  vs.  control,  327/3160
eaths  [10.3%];  RR,  0.86  [95%  CI,  0.74--1.00])  (Table  5).
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d68  
s  there  a  good  cost-beneﬁt  in  the  use  of  GDT  compared
o  standard  treatment  to  reduce  mortality  and  morbidity
n  high-risk  surgical  patients?
RADE:  1C
Response: GDT  implementation  in  high-risk  surgical
atients  undergoing  major  elective  surgery  is  effective  both
linically  and  in  terms  of  cost  compared  to  standard  treat-
ent.  The  implementation  of  additional  costs  may  be  offset
y  savings  from  cost  reduction  due  to  the  reduction  compli-
ation  rates  and  hospital  stay.62
Arguments: Several  studies  have  shown  that  GDT  imple-
entation  in  high-risk  surgical  patients  was  effective  both
linically  and  in  terms  of  cost.  Fenwick63 compared  methods
o  optimize  oxygen  delivery  (using  adrenaline  or  dopex-
mine)  to  reduce  the  risks  associated  with  major  elective
urgery  in  high-risk  patients  and  to  compare  the  costs  and
ost-effectiveness  of  these  approaches.  The  cost-beneﬁt
nalysis  related  the  difference  in  cost  to  the  difference  in
ear  of  life  gained  for  a  follow-up  period  of  two  years.  Ebm55
uggested  that  GDT  in  high-risk  surgical  patients  should  be
horoughly  explored  to  curb  the  increase  in  costs  associated
ith  medical  care.62,64
iscussion
he  ﬂuid  challenge
 ﬂuid  challenge  is  one  of  the  best  tools  that  the  anes-
hetist  has  to  assess  ﬂuid  responsiveness.  For  such,  a  change
n  preload  (ﬂuid  bolus)  should  be  induced  when  monitoring
ubsequent  changes  in  stroke  volume,  cardiac  output,  and
ynamic  indices,  such  as  PPV,  SVV  and  PVI.65
The  use  of  a  ﬂuid  bolus  offers  two  advantages:
1)  A  way  of  assessing  the  response  of  a  patient  to  ﬂuid  using
changes  in  dynamic  and  static  volume  indices,  ﬂow  and
oxygenation;  and
2)  A  change  in  the  increase  of  intravascular  volume  and
often  a  necessary  increase  in  the  ﬂow  (cardiac  output).
A  ﬂuid  bolus  is  a  provocative  test  of  the  circulation,  sim-
lar  to  the  use  of  a  step  function  engineering  to  deﬁne  a
ystem.  A  ‘‘test’’  using  a  small  amount  of  ﬂuid  (bolus)  to
ssess  the  volume  responsiveness  can  reduce  the  risk  of  an
xcessively  liberal  ﬂuid  strategy  and  the  possible  effects  of
uid  overload.  These  tools  help  determine  the  requirements
or  further  ﬂuid  therapy,  preventing  deleterious  effects  of
uid  overload  through  the  administration  of  small  volumes.
Noteworthy,  the  ﬂuid  challenge  technique  is  a  test  of  the
ardiovascular  system;  it  allows  clinicians  to  assess  whether
 patient  has  a  preload  reserve  sufﬁcient  to  increase  stroke
olume  with  more  ﬂuid.  Fluid  therapy  should  be  considered
Rahbari)66 after  a  positive  response  to  a  ﬂuid  challenge.
n  contrast  to  a  single  ﬂuid  challenge,  ﬂuid  may  also  be
dministered  in  a  controlled  manner  based  on  an  algorithm,
epeating  the  ﬂuid  challenge  as  long  as  there  is  a  positive
esponse.  This  controlled  approach  is  called  ‘‘maximizing
troke  volume’’  and  is  the  cornerstone  of  most  goal-directed
herapy  protocols  (Noblett).67 Thus,  the  only  reason  to  per-
orm  a  ﬂuid  challenge  is  to  increase  the  stroke  volume  of
 patient;  if  this  increase  does  not  occur;  it  is  likely  that
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n  additional  administration  of  ﬂuid  is  harmful.  The  only
xcess  ﬂuid  that  can  be  administered  in  a  ﬂuid  challenge  is
he  amount  used  to  which  the  patient  does  not  respond.
A  ﬂuid  challenge  should  comprise  four  separate  orders:
ype  of  ﬂuid  to  be  administered;  volume  of  ﬂuid  to  be  admin-
stered;  infusion  rate;  and  stopping  rules  if  adverse  effects
re  seen  before  the  full  amount  of  the  bolus  is  administered.
or  rapid  infusions  of  very  small  ﬂuid  bolus  (e.g.,  250  mL  of
rystalloid  for  1--2  min),  stopping  rules  are  probably  not  nec-
ssary.  However,  if  larger  amounts  of  ﬂuid  or  longer  infusion
imes  are  used,  it  is  important  to  have  clear  stopping  rules
o  prevent  right  heart  failure  or  pulmonary  edema.
Although  there  is  no  consensus  on  type  or  exact  dosage  of
uid  administration,  boluses  are  delivered  faster  at  a  rapid
ate  (5--10  min)  with  a  quick  evaluation  of  the  physiological
esponse.  The  magnitude  of  this  response  helps  determine
he  ﬂuid  challenge  effectiveness,  as  well  as  the  require-
ents  for  additional  ﬂuid  therapies.  Considering  all  these
spects,  this  approach  avoids  the  deleterious  consequences
f  ﬂuid  overload.  The  peak  and  maintenance  of  the  dynamic
nd  static  variables  improvement  after  a  ﬂuid  bolus  depend
oth  on  physiological  state  and  ﬂuid  composition.  Further-
ore,  the  response  maintenance  after  the  bolus  may  be
educed  in  the  presence  of  continued  bleeding.
We  recommend  bolus  therapy  rather  than  continuous
nfusion  when  the  aim  is  to  improve  the  pressure,  perfusion,
nd  oxygen  delivery.  There  should  be  a  standard  for  ﬂuid
olus  in  relation  to  the  composition  and  ﬂuid  volume,  infu-
ion  rate,  and  post-bolus  evaluation  time.  Variables  used
o  evaluate  the  ﬂuid  bolus  efﬁcacy  should  include  appro-
riate  changes  in  cardiac  output  or  stroke  volume  and,  if
ppropriate,  dynamic  indices  of  ﬂuid  responsiveness.
imitations  of  dynamic  indices
luid  responsiveness  measurements  cannot  be  used  in  all
atients  and,  in  many  it  cannot  be  used  at  all  times.  Dynamic
ndices  have  a  high  predictive  value  in  determining  the
esponsiveness  to  ﬂuid;  however,  speciﬁc  criteria  must  be
et  to  use  these  indices  to  assess  ﬂuid  responsiveness.
ntraoperative  movements,  electrosurgical  equipment,  and
hysiological  artifacts  (noise)  can  interfere  with  the  accu-
ate  interpretation  of  the  dynamic  indexes.  Four  primary
imitations  may  exist  in  the  use  of  dynamic  indexes.
First,  arrhythmias  (e.g.,  atrial  ﬁbrillation)  prevent  the
se  of  PVI,  PPV,  SVV,  and  pulse  wave  velocity  (PWV)  for
redicting  the  ﬂuid  responsiveness,  as  the  variability  of  the
nferior  and  superior  vena  cava  remains  accurate.  The  same
imitation  of  PVI,  PPV,  SVV,  and  PWV  is  observed  in  subjects
hat  show  varying  levels  of  spontaneous  respiratory  efforts.
gain,  the  diameter  variability  of  the  inferior  and  superior
ena  cava  is  still  predictive  of  responsiveness  to  ﬂuid  dur-
ng  spontaneous  breathing.  Second,  if  the  current  volume  is
ess  than  8  mL/kg,  the  negative  predictive  value  of  the  PVI,
PV,  SVV  and  PWV  is  reduced,  while  threshold  range  values
13%  retain  their  positive  predictive  value.  Third,  marked
ecreases  in  chest  wall  compliance  decrease  the  positive
redictive  values  of  all  indices,  while  the  intra-abdominal
ressure  can  mask  hypovolemia,  but  will  not  change  the
redictive  value  of  responsiveness  to  the  volume  of  these
ndices.  Fourth,  in  acute  cor  pulmonale  with  high  ventricular
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interdependence,  it  will  be  observed  a  paradoxical  posi-
tive  value  of  PVI,  PPV,  SVV  or  PWV,  which  will  be  further
increased  upon  ﬂuid  resuscitation.  This  increase  is  due  to
positive  pressure  inspiration  decreasing  the  end-diastolic
volume  in  the  right  ventricle,  allowing  increased  left  ven-
tricular  ﬁlling  and  thus  a  greater  stroke  volume.  However,
the  largest  pulse  pressure  and  stroke  volume  occur  during
inspiration,  while  in  patients  responsive  to  volume,  greater
pulse  pressure  and  stroke  volume  will  occur  during  exhala-
tion.
As  few  clinicians  control  changes  in  ﬂow  and  pressure
on  the  breathing  phase,  and  it  is  known  that  the  patient
has  pulmonary  hypertension  and  cor  pulmonale,  it  is  better
not  to  use  dynamic  indices  alone  to  assess  responsiveness  to
volume.  Recent  studies  have  demonstrated  that  the  intraop-
erative  use  of  PPV/SVV  was  inconclusive  in  identifying  25%  of
patients  requiring  ﬂuid  to  undergo  general  anesthesia.68 The
use  of  these  indices  in  ICU  patients  to  assess  ﬂuid  responsive-
ness  is  even  more  problematic,  with  only  2%  of  ICU  patients
meeting  the  criteria.69 Therefore,  when  dynamic  indices  are
used  to  guide  ﬂuid  therapy,  some  measures  of  increased  per-
fusion  effectiveness  should  be  considered.  In  such  cases,  and
with  the  limitations  of  all  dynamic  indices  listed  above,  it
is  indicated  to  perform  a  ﬂuid  challenge  or  a  passive  leg
elevation  test  to  identify  the  ﬂuid  responsiveness.
Speciﬁcally,  when  any  of  the  above  limitations  prevent
the  use  of  these  parameters,  one  can  consider  perform-
ing  a  passive  leg  elevation  maneuver  (LEM).70 In  contrast  to
mechanical  breathing,  which  usually  reduces  CO,  LEM  cause
an  endogenous  ﬂuid  challenge,  which  will  increase  the  CO
in  ‘‘responsive’’  patients.  LEM  maneuver  have  a  sensitiv-
ity  of  89.4%  and  a  speciﬁcity  of  91.4%  for  predicting  ﬂuid
responsiveness  and  is  best  combined  with  minimally  inva-
sive  cardiac  output  monitors  that  can  control  changes  in
stroke  volume  and  cardiac  output,  dynamically  in  real  time,
regardless  of  ventilation  mode.71,72 LEM  execution,  however,
requires  a  major  change  of  position,  which  often  makes  it
impracticable  for  intraoperative  use.
However,  there  are  cases  in  the  operating  room  (OR)  in
which  postural  changes  can  induce  hemodynamic  response
that  may  serve  as  a  diagnostic  maneuver  for  ﬂuid  respon-
siveness.
Implications
We  recommend  that  hemodynamic  parameters  are  used  as
an  integral  part  of  GDT  protocols.  However,  the  limitations
of  each  dynamic  index  must  be  considered.  The  presence  of
ﬂuid  responsiveness  is  not  an  indication  for  ﬂuid  administra-
tion;  the  ﬁnal  decision  to  give  ﬂuid  must  be  supported  by
the  clear  need  for  hemodynamic  improvement,  presence  of
ﬂuid  responsiveness,  and  absence  of  associated  risks.
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